Related Topics


Companies




  

Category: HIV

Press releases and articles
September 06. 2010
Tibotec seeks European Marketing Authorization for investigational once-daily HIV treatment TMC278
July 28. 2010
Bio-Rad submits premarket approval application to the FDA for its fourth-generation HIV assay
July 27. 2010
Tibotec Pharmaceuticals submits new drug application for investigational once-daily HIV treatment TMC278 to U.S. food and drug administration
July 27. 2010
Abbott to feature novel tests and new upgrades to testing platforms at American Association for Clinical Chemistry Lab Expo
July 20. 2010
BD Biosciences introduces CD4 testing product that does not require refrigeration
July 20. 2010
Research: Merck AIDS drug as effective as Abbott pills
July 20. 2010
Abbott's PROGRESS study of Kaletra and Isentress compared with a standard HIV regimen meets the pre-specified primary efficacy endpoint
June 22. 2010
FDA approves first-of-its-kind HIV test which can detect HIV Days earlier than current U.S. tests
June 09. 2010
Initiation of the first safety trial in Africa of an antiretroviral-containing vaginal ring designed to prevent HIV/AIDS
June 08. 2010
QIAGEN HPV DNA test donation to expand access to cervical cancer screening for women in rural India
June 04. 2010
FDA approves new Roche dual-PCR target HIV-1 test
April 29. 2010
Abbott receives FDA approval for once-daily dosing of Kaletra (lopinavir / ritonavir) for treatment-experienced patients
March 03. 2010
Twenty-five years of HIV blood testing helped to positively transform global health crisis
February 25. 2010
Rate of T cell count drop not found helpful in deciding when to start HIV treatment
February 12. 2010
Abbott receives FDA approval for heat-stable Norvir tablets
February 10. 2010
PREZISTA now approved as part of combination therapy for pediatric patients six years of age and older with HIV
January 26. 2010
Abbott submits new HIV test to FDA for expedited review
January 15. 2010
BD Biosciences collaborates with ReaMetrix to develop new, affordable CD4 testing products to help fight HIV/AIDS in developing countries
December 03. 2009
FDA approves use of Roche test to screen source plasma for HIV, hepatitis B virus and hepatitis C virus
December 02. 2009
Boehringer Ingelheim launches MindBodyHAART.com, a comprehensive online resource for the HIV/AIDS community
November 26. 2009
FDA grants full approval to HIV drug Intelence based on follow-up data from J&J
October 23. 2009
Teva seeks to sell generic version of Bristol HIV drug
October 16. 2009
Ortho Clinical Diagnostics receives FDA approval for first anti-HIV 1+2 test for use on random access, integrated laboratory testing system
October 15. 2009
J&J: Ortho Clinical Diagnostics receives FDA approval for first anti-HIV 1+2 test for use on random access, integrated laboratory testing system
October 08. 2009
Boehringer Ingelheim: Access to HIV medication
September 24. 2009
Sanofi Pasteur commends results of first HIV vaccine study to show some effectiveness in preventing HIV
September 22. 2009
Abbott receives FDA approval for first fully automated blood screening test for HIV-1/HIV-2
September 17. 2009
Boehringer: Head-to-head trial demonstrates Viramune’s similar efficacy and more favourable effect on lipid profile compared to Atazanavir/Ritonavir
July 23. 2009
Abbott HIV test demonstrates earlier disease detection
July 21. 2009
New HIV study shows that large numbers of women and people of color can be successfully enrolled in US HIV clinical studies
July 21. 2009
96-week safety and efficacy findings presented for Intelence as part of HIV combination therapy
July 20. 2009
Head-to-head trial demonstrates Viramune's similar efficacy and superior effect on lipid profile compared to atazanavir/ritonavir
May 08. 2009
HIV/AIDS Research Network recommends use of Abbott RealTime viral load test for NIH-sponsored clinical trials
April 08. 2009
Health Canada approves PREZISTA once daily as part of combination therapy for treatment-naive adults with HIV-1
March 06. 2009
HIV experts propose new approach to eradicate HIV in latest issue of Science
February 19. 2009
A 454 sequencing study reveals new insights in drug resistance and tropism associated with the new HIV integrase and entry inhibitor therapy classes
February 18. 2009
454 Sequencing identifies early stage HIV drug resistance-- low-level mutations may have significant impact on clinical outcomes
February 12. 2009
Prezista® now available for pediatric patients six years of age and older as part of HIV combination therapy
February 11. 2009
Increasing diversity of HIV strains impacts diagnostic test accuracy
February 06. 2009
Tibotec submits application to U.S. Food and Drug Administration seeking traditional approval for INTELENCE
February 04. 2009
Once-daily Prezista for treatment-naïve adults with HIV-1 receives approval in the European Union as part of combination therapy
January 05. 2009
FDA approves Roche's most comprehensive system to test donated blood for HIV, Hepatitis B & Hepatitis C
December 29. 2008
Researchers successfully used the 454 sequencing system for sensitive detection of HIV tropism
December 15. 2008
New Roche dual target HIV-1 test approved for use in European Union
December 04. 2008
Prezista (Darunavir) receives expanded marketing authorisation in the European Union for treatment-experienced adults with HIV-1
November 27. 2008
BD Biosciences announces availability of new CD4 technology in Africa
November 19. 2008
Long-term titan study evaluates Prezista/Ritonavir vs. Lopinavir/Ritonavir as part of HIV combination therapy in treatment-experienced adults
November 13. 2008
Tibotec data presented at ICAAC and HIV9 follow key regulatory approvals for Anti-HIV compounds
October 23. 2008
FDA approves PREZISTA once-daily as part of combination therapy for treatment-naïve adults with HIV-1
September 01. 2008
Abbott fund to build first pediatric HIV/AIDS clinic in Tanzania